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Summary
Artemisinin and its derivatives (ARTs) are frontline antimalarial drugs. However, ART 
monotherapy is associated with a high frequency of recrudescent infection, resulting in treatment 
failure. A subset of parasites is thought to undergo ART-induced latency, but the mechanisms 
remain unknown. Here we report that ART treatment results in phosphorylation of the parasite 
eukaryotic initiation factor-2α (eIF2α), leading to repression of general translation and latency 
induction. Enhanced phosphorylated eIF2α correlates with high rates of recrudescence following 
ART, and inhibiting eIF2α dephosphorylation renders parasites less sensitive to ART treatment. 
ART-induced eIF2α phosphorylation is mediated by the Plasmodium eIF2α kinase, PK4. 
Overexpression of a PK4 dominant-negative or pharmacological inhibition of PK4 blocks parasites 
from entering latency and abolishes recrudescence after ART treatment of infected mice. These 
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results show that translational control underlies ART-induced latency and that interference with 
this stress response may resolve the clinical problem of recrudescent infection.
eTOC paragraph
The antimalarial drug artemisinin is associated with a high frequency of recrudescent infection. 
Zhang et al. identified that artemisinin induces latency through Plasmodium eukaryotic initiation 
factor 2α (eIF2α) phosphorylation. Inhibiting the Plasmodium eIF2α kinase PK4 blocks parasites 
from entering latency and abolishes recrudescence after artemisinin therapy.
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Introduction
The malaria parasite Plasmodium spp. was estimated to cause 212 million new cases and 
over 0.4 million deaths in 2015 (World Health Organization., 2015). Artemisinin and its 
derivatives (ARTs) are the most potent antimalarial drugs to date (Chen, 2016; O’Neill et al., 
2010; Tu, 2011), but their use is stymied by recrudescence rates as high as 60% (Codd et al., 
2011; de Vries and Dien, 1996; Meshnick et al., 1996). Malaria recrudescence, defined as 
the reappearance of the original strain of the parasite after antimalarial medications, is 
considered as treatment failure (Shaukat et al., 2012). To minimize this problem, the World 
Health Organization recommends against monotherapy in favor of ART-based combination 
therapy (ACT). Nevertheless, recrudescent P. falciparum infections have still been reported 
(Ndounga et al., 2015; Yeka et al., 2005).
Most clinical antimalarials are schizonticidal drugs, targeting blood stage parasites that are 
responsible for the clinical symptoms associated with malaria. Within blood cells, 
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merozoites develop to form either gametocytes or schizonts. Plasmodium schizonts release 
daughter merozoites and the free merozoites re-invade erythrocytes and differentiate into 
rings, trophozoites, and schizonts. Recrudescence following antimalarial therapy has been 
thought to occur as a result of drug-resistant parasites (O’Brien et al., 2011). However, 
recrudescent parasites isolated from patients remain sensitive to ARTs (Dondorp et al., 2009; 
Noedl et al., 2008; Phyo et al., 2012). As the in vivo half-life of ARTs is short (Li et al., 
2014), it has been proposed that the concentration of the drug in plasma was insufficient to 
suppress all parasites (White, 2013). Consequently, longer courses of therapy or twice-a-day 
dosing intervals are recommended to efficiently clear the infection (Dogovski et al., 2015). 
Recent studies also indicate that ARTs induce transition of a subset of parasites into latent 
rings that are responsible for recrudescence (Codd et al., 2011; Grobler et al., 2014; LaCrue 
et al., 2011; Teuscher et al., 2012; Teuscher et al., 2010). Despite its clinical importance, the 
molecular mechanism of ART-induced parasite latency remains unknown.
We have previously demonstrated that latent stages of apicomplexan parasites, including 
Toxoplasma and Plasmodium, coincide with increased phosphorylation of the α subunit of 
eukaryotic translation initiation factor-2 (eIF2), which delivers initiator tRNA to ribosomes. 
Phosphorylation of eIF2α, which occurs during cellular stress, results in a reduction of 
general protein synthesis, accompanied by preferential translation of mRNAs encoding 
products that are important for recovery from the stress (Young and Wek, 2016). We 
hypothesized that translation control through parasite eIF2α phosphorylation contributes to 
ART-induced latency. Consistent with this idea, RNA sequencing and microarray studies 
have shown that ribosomal protein genes are down-regulated in response to ART in the 
human malaria parasite, P. falciparum, and the rodent malaria parasite, P. berghei (Shaw et 
al., 2015). Furthermore, proteins involved in the translation process were among the most 
down-regulated gene products in ART-treated parasites (Shaw et al., 2015).
In Plasmodium, there are three eIF2α kinases: eIK1, eIK2, and PK4 (Ward et al., 2004). The 
eIK1 protein kinase responds to amino acid deprivation during the erythrocytic stage 
(Babbitt et al., 2012; Fennell et al., 2009), while eIK2 controls sporozoite latency in the 
mosquito salivary glands (Zhang et al., 2010). Neither eIK1 nor eIK2 are essential for 
erythrocytic stage development (Fennell et al., 2009; Zhang et al., 2010). In contrast, PK4 
phosphorylates eIF2α in mature schizonts and is essential for parasite development in 
erythrocytes (Solyakov et al., 2011; Zhang et al., 2012a). In this study, we establish that 
eIF2α phosphorylation by PK4 is critical for the ART-induced latency that leads to 
recrudescence and treatment failure. Importantly, small molecule inhibition of PK4 blocks 
the ability of the parasite transition into this latent phase and as a consequence prevents 
malaria recrudescence following ART treatment.
Results
ART induces eIF2α phosphorylation in Plasmodium
Phosphorylation of eIF2α has been associated with slow-growing and latent stages of 
parasite development (Babbitt et al., 2012; Fennell et al., 2009; Zhang et al., 2013; Zhang et 
al., 2012a). We sought to determine the status of eIF2α phosphorylation in malaria parasites 
treated with ARTs as well as recrudescent parasites post-ART treatment. Two derivatives of 
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artemisinin have been employed to study malaria recrudescence: dihydroartemisinin (DHA) 
is used in cultured human malaria and artesunate (AS) in rodent malaria (Chen et al., 2014; 
Codd et al., 2011; LaCrue et al., 2011; Peatey et al., 2015; Shaw et al., 2015; Teuscher et al., 
2012; Teuscher et al., 2010). We established recrudescence post-AS treatment in P. berghei 
ANKA infected Swiss Webster mice (Figure S1 and Table S1). Phosphorylation of P. 
berghei eIF2α (PbIF2α) was significantly enhanced following AS treatment and 
dephosphorylated in the recrudescent parasites (Figure 1A). Similar results were observed in 
P. falciparum cultures treated with DHA followed by magnetic column purification to 
remove parasites unaffected by DHA (Figure 1B) (Teuscher et al., 2010). High levels of 
Plasmodium eIF2α phosphorylation in the small population (<1%, Figure S2) of latent 
parasites induced by ART were maintained with salubrinal (Sal) treatment, which has been 
established to inhibit the dephosphorylation of eIF2α in multiple species, including 
apicomplexan parasites (Tsaytler and Bertolotti, 2013; Zhang et al., 2010) (Figure 1C). 
Addition of Sal to the latent parasites delayed parasite recrudescence in a dose-dependent 
manner (Figures 1D, 1E and S2). These results show that ARTs induce eIF2α 
phosphorylation in Plasmodium, which is then removed in recrudescing parasites.
Parasites bearing phosphorylated eIF2α are less sensitive to ART
Blood stage schizogony is a replicative process in which the parasite undergoes multiple 
rounds of nuclear division: ring stages differentiate to trophozoites and then mature into 
schizonts, which rupture and release merozoites. Free merozoites invade other erythrocytes 
to continue the asexual blood-stages of the life cycle. Phosphorylation of Plasmodium eIF2α 
was not detectable in rings or trophozoites, but was observed in late schizonts (Figures 2A 
and B), consistent with the diminished protein synthesis seen in late schizonts (Fang et al., 
2014; Zhang et al., 2012a). Schizonts bearing enhanced levels of phosphorylated eIF2α 
were associated with high rates of recrudescence following ART treatment (Figures 2C and 
D). The level of eIF2α phosphorylation was significantly enhanced in rings in response to 
ART treatment (Figures 2A and B). Recrudescence occurred in ring stages following ART 
treatment compared with trophozoites (Figures 2C and D). Thus, ARTs induce ring-stage 
parasites to increase the levels of phosphorylated eIF2α and ring-stage parasites are less 
sensitive to ARTs.
Inclusion of Sal in either P. berghei or P. falciparum cultures increases the amount of eIF2α 
phosphorylation (Figures 2E and F). Enhanced Plasmodium eIF2α phosphorylation 
coincided with the parasites being less sensitive to ART treatment (Figures 2G and H), 
suggesting that translational control has a protective effect against the drug. Recrudescence 
following AS exposure occurred in all mice pretreated with Sal, compared to a 20–40% 
recrudescence rate in control groups with only basal levels of PbeIF2α phosphorylation. In 
addition, recrudescence occurred earlier in some mice pretreated with Sal. The earlier 
recrudescence following ART treatment was also observed in P. falciparum cultures 
pretreated with Sal. These findings show that increased levels of phosphorylated eIF2α 
protects parasites from ART treatment.
The effect of Sal on the parasite’s recrudescence post ART therapy depends on the time of 
Sal delivery. In the scenario of adding Sal after ART therapy, recrudescence was postponed 
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(Figures 1D and E). The explanation for this finding is that the parasite transits to latency 
after ART therapy, and adding Sal to the latent parasite prolongs the latency by maintaining 
the eIF2α phosphorylation level. In the scenario of adding Sal prior to ART therapy, the 
recrudescence occurred earlier and with higher rate (Figures 2G and H). The rationale for 
this observation is that pretreatment of Sal increases eIF2α phosphorylation level and the 
parasite transits into latency before ART therapy. The latent parasite is tolerant to ART 
treatment.
ART exposure activates the ER-resident eIF2α kinase, PK4
Three eIF2α kinases have been identified in Plasmodium: eIK1, eIK2, and PK4 (Tewari et 
al., 2010; Ward et al., 2004). We determined whether parasites lacking each of these eIF2α 
kinases exhibited a defect in recrudescence following ART treatment. Figure S3 shows our 
successful generation of PbeIK1 (−) parasites, and our generation of PbeIK2 (−) parasites 
was described earlier (Zhang et al., 2010). PbeIK1 (−) and PbeIK2 (−) parasites proliferated 
normally in erythrocytes (Figure S3C) and no defect was observed in the enhanced eIF2α 
phosphorylation in response to AS treatment (Figure S4A). Moreover, mice infected with 
either PbeIK1 (−) or PbeIK2 (−) parasites and treated with 3 or 5 doses of AS showed the 
same degree of recrudescence as wild-type (Figures S4B and S4C). These results show that 
neither PbeIK1 nor PbeIK2 contributes to AS-induced latency.
Plasmodium PK4, which has been shown to be essential for the parasite (Solyakov et al., 
2011; Tewari et al., 2010; Zhang et al., 2012a), is related to the human eIF2α kinase, PERK. 
Like PERK, PK4 contains a predicted transmembrane domain situated upstream of its 
protein kinase domain (Figure 3A). Also like PERK (Harding et al., 1999), we found that 
PK4 localizes to the parasite endoplasmic reticulum (ER) (Figure 3B and S5) in a complex 
with the ER-resident chaperone BIP (Kumar et al., 1991) (Figure 3C). We previously 
verified that the kinase domain of PK4 is able to phosphorylate eIF2α using an in vitro assay 
(Zhang et al., 2012a). Notably, this reaction required oligomerization via the fused GST 
domain for both eIF2α phosphorylation and autophosphorylation of PK4 (Zhang et al., 
2012a), which is consistent with the reported mechanism of PERK activation (Harding et al., 
1999; Walter and Ron, 2011). Additionally, we show that endogenous PK4 oligomerized 
post DHA treatment (Figure 3D), supporting the idea that oligomerization of PK4 leads to 
enhanced phosphorylation of eIF2α in response to AS in 15 min (Figures 2B). Of 
importance, ART treatment also led to displacement of BIP from PK4, which coincides with 
PK4 oligomerization/autophosphorylation, and eIF2α phosphorylation, which are processes 
that are also important for activation of PERK. Taken together, the results indicate that 
Plasmodium ER-resident eIF2α kinase PK4 phosphorylates eIF2α in response to AS 
treatment using a mechanism of kinase activation that is analogous to PERK.
Expression of a dominant-negative form of PK4 blocks recrudescence
Since PK4 is essential (Zhang et al., 2012a), we used a dominant-negative strategy to study 
its role in AS-induced latency and recrudescence. A dominant-negative version of PK4 was 
created by mutating the autophosphorylation site in PbPK4, threonine-2436 (Zhang et al., 
2010); the mutation ablated PK4 autophosphorylation and eIF2α phosphorylation (Figure 
4A). An episomal plasmid was engineered to express the T2436A PK4 mutant or a control 
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version containing a change to a synonymous threonine codon (wt). These plasmids were 
transfected into P. berghei schizonts, which were then inoculated into mice. It was 
previously shown that expression of a mutant version of PERK can oligomerize with 
endogenous wild-type kinase and lower eIF2α (Ma et al., 2002). Six hours later when the 
parasites had developed into rings, PK4 mRNA levels representing the endogenous, 
synonymous, and T2436A mutant were analyzed by qRT-PCR. The mRNA levels of 
T2436A PK4 were 10-fold higher than that of endogenous PK4 (Figure 4B). The mRNA 
levels of wild-type PK4 in the parasites transfected with the synonymous PK4 expression 
cassette were ~2-fold higher relative to the parasites transfected with empty vector. Similar 
results were also reported for the same mutated version of a related mammalian eIF2α 
kinase (Romano et al., 1998). Overexpression of eIF2α kinases inhibits translation and 
eukaryotic cell growth, but analogous expression of a mutant eIF2α kinase lacking activity 
are tolerated and therefore can be expressed at higher levels. At the protein level, total PK4 
was increased in synonymous and dominant-negative PK4 overexpressing parasites (Figure 
4C). As expected, eIF2α phosphorylation was increased in parasites expressing the 
synonymous PK4 mutation, and protein synthesis was inhibited in these parasites 
accordingly (Figure 4D). Conversely, levels of eIF2α phosphorylation were decreased in 
parasites expressing the T2436A PK4 mutant (Figure 4C), with a corresponding alleviation 
of translational repression (Figure 4D). Recrudescence following ART treatment occurred 
earlier and at a higher rate in parasites transfected with the functional PK4 containing a 
synonymous codon change, whereas no recrudescence was observed in parasites transfected 
with dominant-negative version of PK4 (Figure 4E). These findings further support the 
model that interference with PK4-mediated eIF2α phosphorylation blocks the ART-induced 
latency that leads to recrudescent infection.
Pharmacological inhibition of PK4 blocks parasite differentiation from trophozoites into 
schizonts and attenuates recrudescence
We used another approach to test whether PK4 inhibition blocks ART-induced latency. 
Parasites were treated with GSK2606414, an established inhibitor of PERK (Axten et al., 
2012). We first confirmed that PK4 kinase activity was specifically inhibited by 
GSK2606414 in vitro, and that GSK2606414 had no effect on eIK1 or eIK2 (Figure S6A–
C). We next measured the effect of GSK2606414 on P. berghei-infected mice and P. 
falciparum cultures. GSK2606414 inhibits eIF2α phosphorylation in asynchronized 
parasites (Figures 5A and B). In the control groups, asynchronized parasites containing all 
stages showed schizonts bearing phosphorylated eIF2α (Figures 2A, 2B, 5A, and 5B). 
GSK2606414 reversibly inhibited parasite development in erythrocytes (Figures 5C, 5D and 
S6D–F), consistent with previous findings that the phosphorylation of eIF2α by PK4 is 
essential for the development of the parasite in the erythrocytic cycle (Solyakov et al., 2011; 
Zhang et al., 2012a). During GSK2606414 treatment, parasites entered the trophozoite stage 
but did not progress to schizogony (Figure 5E and S6E), which is consistent with our 
previous observation that PK4 phosphorylates eIF2α in late schizonts (Zhang et al., 2012a). 
We conclude that the inhibition of eIF2α phosphorylation by GSK2606414 disrupts parasite 
differentiation from trophozoites into schizonts.
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We next addressed whether GSK2606414 could affect ART-induced latency and 
recrudescent infection by inhibiting the PK4-mediated eIF2α phosphorylation that occurs in 
response to ART. The combination of ART and GSK2606414 abolished parasite 
recrudescence in P. berghei-infected mice and P. falciparum cultures (Figure 5F and G), 
suggesting that inhibition of PK4 restores parasite sensitivity to ART.
PfeIF2α phosphorylation in the ART-resistant parasite Dd2C580Y
A transcriptome survey of P. falciparum clinical isolates found that ART resistance is 
associated with increased expression of genes involved in the unfolded protein response 
(UPR) pathways and with arrest in rings (Mok et al., 2015). In mammalian cells, the UPR is 
a cellular stress response resulting in phosphorylation of eIF2α. Phosphorylation of eIF2α 
can promote mammalian cell survival under stress (Ron and Walter, 2007; Walter and Ron, 
2011). We sought to determine the status of eIF2α phosphorylation in the ART-resistant 
parasite Dd2C580Y before and after DHA treatment. PfK13-propeller mutations, including 
C580Y, confer ART resistance in P. falciparum (Straimer et al., 2015). The ART-sensitive 
and chloroquine-resistant parasite line Dd2 was included as a control. PfeIF2α was 
phosphorylated in the young ring-stage of the ART-resistant parasite Dd2C580Y, but not in 
the young ring-stage of the ART-sensitive parasite Dd2 (Figure 6A). However, PfeIF2α was 
dephosphorylated in late rings and trophozoites. The phosphorylation of eIF2α in late 
schizont-stage was observed in both sensitive and resistant parasites. The ART-resistant 
parasite Dd2C580Y remained in a state of decelerated development at ring stage in culture. At 
40 hours, the ART-resistant parasite reached the late schizont-stage just like the sensitive 
parasite (Figure 6A). This is consistent with the phenotype of ex-vivo culture of clinical 
ART-resistant isolates (Mok et al., 2015). Nevertheless, DHA did not induce higher levels of 
PfeIF2α phosphorylation in the ART-resistant parasite Dd2C580Y, in contrast to that 
observed in the sensitive Dd2 (Figure 6B). GSK2606414 reduced ART resistance in the 
parasite Dd2C580Y (Figure 6C). An explanation of these results is that PfeIF2α is basally 
phosphorylated in the young rings of the ART-resistant parasite, likely by PK4, and the 
resistant parasite do not response to DHA by phosphorylating eIF2α compared to the ART-
sensitive parasite.
Discussion
ARTs are a formidable weapon against malaria, but a small proportion of parasites become 
latent during treatment and later reemerge in a phenomenon known as recrudescence (Cheng 
et al., 2012; Codd et al., 2011; LaCrue et al., 2011; Teuscher et al., 2012; Teuscher et al., 
2010). These recrudescent parasite isolates are not drug-resistant, suggesting that disruption 
of latency could remedy the treatment failure (Dondorp et al., 2009; Noedl et al., 2008; Phyo 
et al., 2012). Our findings indicate that the Plasmodium eIF2α kinase PK4 is localized to the 
parasite ER and is activated by oligomerization and autophosphorylation in response to 
ARTs. Activated PK4 phosphorylates eIF2α and inhibits global protein synthesis, promoting 
latency and providing for an adaptive state that allows for the parasite to better manage the 
damage accrued upon exposure to ARTs. Attenuation of PK4 activity through expression of 
a dominant-negative PK4 or application of a PERK inhibitor was successful in curbing 
recrudescent infection.
Zhang et al. Page 7
Cell Host Microbe. Author manuscript; available in PMC 2018 December 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ART contains an endoperoxide group that causes oxidative stress, which leads to parasite 
clearance (O’Neill et al., 2010). Upon entering parasites, ARTs have been reported to traffic 
to a wide variety of subcellular organelles, including the ER, food vacuole, mitochondrion 
and other membrane-bound organelles (Eckstein-Ludwig et al., 2003; Hartwig et al., 2009; 
Stocks et al., 2007; Wang et al., 2010) and result in protein damage (Chen et al., 2017). 
ARTs induce PK4 activation in the ER of ring stages, resulting in the phosphorylation of 
eIF2α that promotes latency associated with recrudescent infection (Cheng et al., 2012; 
Codd et al., 2011; LaCrue et al., 2011; Teuscher et al., 2012; Teuscher et al., 2010). Ring 
stage parasites respond to ARTs by phosphorylating eIF2α (Figure 2), which is concordant 
with previous reports describing the induction of latent rings by ARTs (Grobler et al., 2014; 
LaCrue et al., 2011; O’Brien et al., 2011; Teuscher et al., 2012; Teuscher et al., 2010; Tucker 
et al., 2012; Witkowski et al., 2010).
In response to diverse stress stimuli, eukaryotic cells activate an adaptive pathway termed 
the integrated stress response (ISR) to restore cellular homeostasis. The ISR centers on the 
ability of cells to modulate translation of mRNAs through the phosphorylation of eIF2α. 
Severe or prolonged stress will overwhelm the capacity of the adaptive response and initiate 
cell death (Pakos-Zebrucka et al., 2016). Plasmodium activates the parasitic ISR by 
phosphorylating eIF2α in response to diverse cell perturbations, including stress induced by 
drugs such as ART or chloroquine (Surolia and Padmanaban, 1991), or amino acid 
deprivation (Babbitt et al., 2012; Fennell et al., 2009). The percentage of parasites that 
retreat into a latent state during ART treatment depends on the initial parasitemia and drug 
dosage (Klonis et al., 2013; Teuscher et al., 2012). Longer courses of therapy or shorter 
intervals (e.g., twice daily regimen) are recommended to efficiently clear parasite infections 
(Dogovski et al., 2015). The recrudescence rate of a twice-daily regimen was lower than a 
once-daily regimen (Figure S1).
Recrudescence has also been reported to occur during monotherapy with other first-line 
antimalarial drugs (Bennett et al., 2013; Happi et al., 2004; Kugasia et al., 2014). Some 
clinical drugs have less inhibitory effect on schizonts compared with trophozoites (Table 1). 
Of interest, Plasmodium eIF2α is basally phosphorylated in schizonts (Figures 2A and B), 
which likely explains their decreased sensitivity to drugs, including ART therapy (Klonis et 
al., 2013; LaCrue et al., 2011; Sullivan, 2013). The median lethal dose (LD50) of DHA in the 
parasite rings and late schizonts is higher than that of trophozoites (Klonis et al., 2013; 
Sullivan, 2013). Latency induced by eIF2α phosphorylation during the schizont stage may 
be triggered by the depletion of hemoglobin from host erythrocytes, leading to nutritional 
deprivation. The decreased drug sensitivity in the schizonts indicates that latency triggered 
by an underlying stress is accompanied by activation of an eIF2α kinase which provides the 
parasite protection against a subsequent stresses, including those caused by drug exposure. 
This pre-conditioning mechanism affords the parasite an adaptive strategy that also helps to 
explain previous findings that Plasmodium preferentially progress to arrest as schizonts in 
response to antimalarials (Wilson et al., 2013). Consistent with this idea, augmentation of 
eIF2α phosphorylation by virtue of Sal increased recrudescence rates to 100% (Figure 2G). 
Additional mechanisms may also contribute to schizonts being less sensitive to some drugs. 
Clearly, the role of Plasmodium eIF2α phosphorylation in response to other clinical 
antimalarial drugs requires further investigation.
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As proof of concept, we tested the PERK inhibitor, GSK2606414, on Plasmodium PK4 and 
subsequently malaria infection models. GSK2606414 inhibited PK4 alone, with no effect on 
the other two Plasmodium eIF2α kinases that respond to alternative stress signals (Figure 
S6). Importantly, GSK2606414 inhibited Plasmodium eIF2α phosphorylation and abolished 
recrudescence post-ART therapy (Figure 5). Since the ER, and hence PERK, are absent in 
mature erythrocytes, GSK2606414 is most likely exerting its activity through the parasite. In 
agreement with the PERK inhibitor study, over-expression of a mutated PK4 lacking eIF2α 
kinase activity also inhibited recrudescence (Figure 4). Together, these results show that 
interference with the PK4-mediated stress response pathway offers a means to resolve the 
clinical problem of recrudescent infection.
In addition to recrudescence that has been reported decades ago (Li et al., 1984), the 
emergence and spread of ART resistance in recent years threatens malaria control and global 
public health (Dondorp et al., 2009). A transcriptome survey of P. falciparum clinical 
isolates found that ART resistance is associated with increased expression of genes in the 
unfolded protein response (UPR) (Mok et al., 2015). In mammalian cells, the UPR is a 
cellular stress response that is regulated by phosphorylation of eIF2α (Ron and Walter, 
2007; Walter and Ron, 2011). Lowered global protein synthesis controlled through PfeIF2α 
phosphorylation could explain slow growth in the young rings of ART-resistant parasites 
(Mok et al., 2015) (Figure 6A). The young rings of ART-resistant parasite Dd2C580Y are 
latent, and the phosphorylation levels of PfeIF2α were not changed in response to 700 nM 
DHA treatment for 15 min by (Figure 6B). PfeIF2α phospohorylation level in different 
erythrocytic stages of clinical isolates post longer time ART treatment requires further 
investigation. In higher eukaryotic cells, basal phosphorylation of eIF2α is responsible for 
resistance to stress induced cell death (Zeng et al., 2011). Phosphorylation of PfeIF2α may 
be responsible for resistance to ARTs. The eIF2α kinase responsible for PfeIF2α 
phosphorylation in ART-resistant parasites has not yet been identified. As PERK appears to 
be the only UPR responder conserved in Apicomplexa, it makes for a highly attractive drug 
target. PK4 is homologous to the human eIF2α kinase PERK, and essential for the parasite 
erythrocytic cycle (Solyakov et al., 2011; Zhang et al., 2012a). Nevertheless, GSK2606414 
reversibly inhibits the parasite differentiation into schizont and does not kill the parasite 
(Figure 5D,E and S6D–F). This result is consistent with the previous finding that the 
barcode of the PK4 mutant was still detected in the mouse 4–8 days post transfection of PK4 
knockout plasmid (Gomes et al., 2015). The PK4 inhibitor GSK2606414 reduced ART 
resistance in Dd2C580Y (Figure 6C), and PK4 may be responsible for phosphorylating 
PfeIF2α in the ART-resistant parasite. Further investigation into the translational control, 
including genetically validating the PfeIF2α kinase, in ART-resistant parasites may reveal 
additional ways to interfere with this critical pathway.
It has been reported that P. falciparum phosphatidylinositol-3-kinase (PfPI3K) and its lipid 
product phosphatidylinositol-3-phosphate (PI3P) are increased in ART-resistant parasites, 
and PI3P is the key mediator of ART resistance (Mbengue et al., 2015). It is of interest to 
investigate the relationship between the PfPI3K/PI3P and PfPK4/PfeIF2α pathways using 
the PfPK4 inhibitor GSK2606414.
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The discovery that translational control is critical for parasite recrudescence has far-reaching 
implications for other parasites with latent stages relevant to pathogenesis, such as 
Toxoplasma gondii. Toxoplasma is currently incurable because treatment of the replicative 
stage is believed to drive a subset of parasites back into the latent tissue cyst stage. It would 
be worthwhile to determine whether disruption of eIF2α phosphorylation during drug 
treatment of toxoplasmosis prevents the formation of additional tissue cysts.
STAR METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-Plasmodium eIF2α-P William J. Sullivan, Jr (Narasimhan et al., 2008b)
Anti-total Plasmodium eIF2α William J. Sullivan, Jr (Sullivan et al., 2004)
Anti-Plasmodium PK4 This paper N/A
Anti-Plasmodium BIP Nirbhay Kumar (Kumar et al., 1991)
Parasites
P. berghei ANKA NYU Insectary Core 
Facility and Parasite 
Culture
https://med.nyu.edu/microbiology-parasitology/research/parasitology/insectary-core-facility-and-parasite-culture
P. falciparum 3D7 NYU Insectary Core 
Facility and Parasite 
Culture
https://med.nyu.edu/microbiology-parasitology/research/parasitology/insectary-core-facility-and-parasite-culture
P. falciparum Dd2 David Fidock (Straimer et al., 2015)
P. falciparum Dd2C580Y David Fidock (Straimer et al., 2015)
PbeIK1 (−) This paper Figure S3
PbeIK2 (−) Victor Nussenzweig (Zhang et al., 2010)
Chemicals, Peptides, and Recombinant Proteins
Artesunate Tokyo Chemical 
Industries Co. Ltd.
Cat#A2191
Dihydroartemisinin AK Scientific, Inc. Cat#K453
Salubrinal Tocris Bioscience Cat#2347
GSK2606414 MedChemexpress Cat#HY-18072
Amodiaquin Sigma-Aldrich Cat#1031004
Atovaquone Sigma-Aldrich Cat#A7986
Pyrimethamine Sigma-Aldrich Cat#46706
Primaquine Sigma-Aldrich Cat# 1561507
Recombinant Protein GST-PbPK4KD 
T2436A mutant
This paper N/A
Recombinant Protein GST-PfPK4KD This paper N/A
Recombinant Protein GST-PfeIK1KD This paper N/A
Recombinant Protein GST-PfeIK2KD This paper N/A
Recombinant Protein PfeIF2α-His This paper N/A
Experimental Models: Cell Lines
Human red blood cells Interstate Blood Bank http://www.interstatebloodbank.com/products.asp
Experimental Models: Organisms/Strains
Mouse Swiss Webster Taconic Biosciences Tac:SW
Oligonucleotides
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REAGENT or RESOURCE SOURCE IDENTIFIER
wt PbPK4 qPCR
caaatgattggaacccctggatataca
This paper N/A
synonymous PbPK4 qPCR
cagatgataggtacgccaggttacact
This paper N/A
PbPK4 T2436A mutant qPCR
cagatgataggtgcaccaggttacact
This paper N/A
PbArgRS qPCR Eurofins (Zhang et al., 2010)
Recombinant DNA
plasmid pBC_PbeIK1KO This paper N/A
plasmid pGST-PfeIK1KD This paper N/A
plasmid pGST-PfeIK2KD This paper N/A
plasmid pGST-PfePK4KD This paper N/A
plasmid pPfeIF2α-His This paper N/A
plasmid pPK4wt episome This paper N/A
plasmid pPK4T2436A episome This paper N/A
plasmid pVector episome This paper N/A
Software and Algorithms
DNASTAR DNASTAR, Inc. https://www.dnastar.com/
Applied Biosystems 7500 Fast Real-
Time PCR System
Applied Biosystems http://www.appliedbiosystems.com/absite/us/en/home/support/software/real-time-pcr/ab-7500.html
Prism GraphPad Software, Inc. https://www.graphpad.com/
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Min Zhang (zhanmin@iu.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal model—All animal work has been conducted according to Institutional Animal 
Care and Use Committee (IACUC) Laboratory Animal Protocol: 140102. Six-eight week 
old female Swiss Webster mice from Taconic Biosciences (genetics: recessive mutation 
Pde6brd1) were used in this study. All animals were housed at New York University Medical 
Center animal facilities under the care of the Division of Laboratory Animal Resources 
veterinary staff.
Human cells—Human red blood cells from O+ Caucasian donors were purchased from 
Interstate Blood Bank with authentification. All work on P. falciparum has been conducted 
according to Institutional Biosafety Committee protocols 16-000072 and IN-777. P. 
falciparum infected red blood cells were cultured in RPMI-based medium containing 5 mM 
glucose, 25 mM HEPES, 2 g/L NaHCO3, 100 μM hypoxanthine, 50 μg/L gentamicin and 
5% Albumax II, pH 7.2 at 37 °C in a mixture of nitrogen (90%), CO2 (5%) and Oxygen 
(5%).
METHODS DETAILS
Drugs—Artesunate (AS) used in this study was obtained from Tokyo Chemical Industries 
Co. Ltd. The AS powder was dissolved in ethanol to make a 21 mg/mL stock, which was 
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further diluted with water to the administrated concentration and immediately introduced 
into the stomach of mice with an oral gavage cannula at 64 mg/kg mouse body weight as 
previously described (LaCrue et al., 2011). Dihydroartemisinin (DHA) used in this study 
was obtained from AK Scientific, Inc. DHA was dissolved in DMSO to make a 1 mM stock. 
P. falciparum 3D7 culture was treated with 200 nM DHA for 6 hours, followed by magnetic 
column purification for 3 consecutive days to remove unaffected parasites by the drug as 
previously described (Teuscher et al., 2010). The in vivo half-lives of AS and DHA are 
within one hour (O’Neill et al., 2010). Sal was obtained from Tocris bioscience and prepared 
as a 100 mM stock solution in DMSO. P. berghei infected mice were intravenously injected 
with Sal at 2 mg/kg mouse body weight. P. falciparum culture was treated with Sal at 10 μM. 
The half-life of Sal in plasma is approximately 6 hours (Zhang et al., 2012b). GSK2606414 
was obtained from MedChemexpress and prepared as a 100 mg/mL stock solution in 
DMSO. P. berghei infected mice were i.v. injected with 75 mg/kg of GSK2606414 in a 
solution with 0.5% hydroxypropyl methylcellulose and 0.1% Tween 80. P. falciparum 
culture was treated with GSK2606414 at 2 μM.
Giemsa stain to monitor recrudescence—Thin blood smears were made from P. 
berghei infected mice and P. falciparum culture, followed by 100% methanol fixation and 
1:10 diluted Giemsa solution for 10 min. Parasitemia were calculated by counting the 
normal erythrocytic stages, including replicative rings, trophozoites and schizonts.
Parasite purification and SDS-PAGE—After 3 doses of 64mg/kg AS treatment, P. 
berghei parasitized mouse blood was collected and the blood cells were washed twice in 
RPMI 1640. Then the red blood cells were collected after separation by Histopaque-1077 
gradient centrifugation. Collected mouse red blood cells were then lysed with 0.2 % (w/v) 
saponin in PBS to released parasites. Parasite pellets were lysed and resuspended in SDS-
PAGE loading buffer. Parasite proteins were resolved by SDS-PAGE and transferred to 
PVDF membrane for immunoblot. P. falciparum infected human red blood cells were treated 
with 200 nM DHA for 6 hours, followed by magnetic 3-step column purification to remove 
unaffected parasites by the drug (Teuscher et al., 2010).
Antiserum—The C-terminus of PK4 (outside of the kinase domain) fused with GST was 
expressed in E. coli, and the purified protein was used to immunize BALB/c mice. 
Immunoblot of P. berghei parasite lysates with the mouse serum (1:3,000 dilution) revealed a 
major band >290 kDa (endogenous PbPK4 is 310 kDa). PfBIP is a major ER chaperone 
protein (Kumar et al., 1991). The rabbit anti-PfBIP serum that was generated by 
immunization with a polypeptide consisting of the the last 11 amino acid residues of PfBIP 
was used to detect PbBIP (Kumar et al., 1991). This portion of BIP is highly conserved 
among the Plasmodium species (Roobsoong et al., 2014). The anti-total eIF2α and anti-
eIF2α-P sera were generated in the laboratory of William J. Sullivan Jr., and used in 
Plasmodium as previously described (Narasimhan et al., 2008a; Zhang et al., 2010; Zhang et 
al., 2016).
Generation of PbeIK1(−) parasites—PbeIK1 knockouts were generated using the same 
method that we previously described for generation of PbeIK2 (−) parasites (Zhang et al., 
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2010). The 3′-terminal of PbeIK1 coding sequence in the genome (PbANKA_130840, 
4.5kb) is adjacent (less than 500 bp) to PbANKA_130830. We deleted the 5′-terminus (2.5-
kb) of the PbeIK1 coding sequence to avoid interference with the downstream gene. The 
2.5-kb of the 5′-portion of this gene encodes the entire eIF2α kinase catalytic domain 
(Zhang et al., 2010).
Overexpression of dominant-negative or wt PK4—The PbPK4 expression cassette 
contains 1.2-kb of the 5′-untranslated region (UTR), PbPK4 coding sequence, and 1.0-kb of 
the 3′-UTR. The sequence around the threonine 2436 in endogenous PbPK4 is 
caaatgattggaacccctggatataca (T2436 underlined); the sequence around the threonine 2436 in 
synonymous version of PbPK4 is cagatgataggtacgccaggttacact (T2436 underlined, and 
synonymous mutations marked in bold); the PbPK4 sequence with the alanine 2436 codon 
mutant is cagatgataggtgcaccaggttacact (A2436 underlined, and mutations marked in bold). 
Vector pUC57 encoding PbPK4 with the synonymous or T2436A codons were transfected 
into P. berghei ANKA mature schizonts as previously described (Janse et al., 2006). Empty 
vector was a control. The transfected schizonts were intravenously injected to mice. Six hour 
later when the parasites developed into ring stage, the recipient mice were used to analyze 
PK4 mRNA level, total PK4 protein level, eIF2α phosphorylation level, and protein 
synthesis.
In Vitro kinase Assay—GST-tagged PfPK4 kinase domain was expressed and purified 
from E. coli. The purified GST-PfPK4KD and PbeIF2α were incubated with 20 μCi 
[γ-32P]ATP in a final concentration of 50 μM and kinase buffer solution (15 mM Hepes [pH 
7.5], 100 mM NaCl, 2 mM TCEP, 5 mM MgCl2) in a volume of 50 μL at 37 °C for 5–60 
min. The GST-PfPK4KD protein was pre-incubated with GSK2606414, and PbeIF2α and 
[γ-32P]ATP were added. Proteins were then separated by SDS-PAGE, followed by 
autoradiography.
Glycerol-gradient sedimentation—The lysis buffer (1% Triton x 100, 150 mM NaCl, 
10% glycerol, 1 mM EDTA, 20 mM Hepes [pH 7.5]) was used to extract Plasmodium 
membrane proteins. Extracts were centrifuged through 20–40% glycerol gradients in 
polyallomer tubes of 11X 60 mm as described for the human eIF2α kinase PERK (Bertolotti 
et al., 2000; Ma et al., 2002). Each 4-mL gradient was divided into eight equal fractions of 
500 μL. Aliquots of each fraction were subjected to SDS–PAGE after adjustment of the 
glycerol concentration in each fraction to 20%, and the contents of PK4 and BIP were 
measured by immunoblots.
Quantification and Statistical Analysis
P. berghei recrudescence in mouse: Five Swiss Webster mice per group were used to 
monitor parasitemia of P. berghei in Figure 1D, 2C, 2G, 4E, 5C, 5D, and 5F. Ten Swiss 
Webster mice per group were used to monitor parasitemia of P. berghei in Figure S1, S3C, 
S4B and S4C.
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Giesma stains, immunoblots, immunoflorescence assay, and P. facliparum 
recrudescence assay: Three independent experiments were performed to confirm the 
reproducibility, and data are representative of 3 independent experiments.
The mRNA levels of PK4 and incorporation of [35S]Met/Cys: Two independent 
experiments were performed to evaluate the mRNA levels of PK4 and the incorporation of 
[35S]Met/Cys. Each value is the mean ± standard deviation (SD) of independent experiments 
(Figure 4B and 4D).
RSA survival rate: Five independent experiments were performed to evaluate RSA survival 
rate (Figure 6C). The normality assumption was tested using the Shapiro-Wilk test. 
Statistically significant differences were determined by the Student’s t-test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Plasmodium eIF2α kinase PK4 is activated upon artemisinin treatment
• eIF2α phosphorylation by PK4 leads to latency and recrudescence post 
artemisinin therapy
• Inhibiting PK4 abolishes recrudescence after artemisinin therapy
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Figure 1. Phosphorylation of eIF2α in response to ART treatment in Plasmodium parasites
(A) P. berghei ANKA infected mice were treated with 3 doses of AS (64 mg/kg/dose, 12-
hour interval), and AS-treated parasites were collected 6 hours after the final dose of AS. 
Parasite recrudesced 8 days post-AS treatment, and the recrudescent parasites were collected 
on day 8. The levels of phosphorylated PbeIF2α (PbeIF2α-P) and total PbeIF2α were 
measured by immunoblot in the untreated, AS-treated and recrudescent parasites. (B) 
Asynchronized P. falciparum 3D7 culture was treated for 6 hours with 200 nM DHA 
followed by magnetic column purification to remove unaffected parasites by the drug. DHA-
treated parasites were collected immediately after column purification. Parasite recrudesced 
12 days post-DHA treatment, and the recrudescent parasite were collected on day 12. The 
untreated parasites without magnetic column purification were included as a control. Levels 
of PfeIF2α-P and total PfeIF2α in the untreated, DHA-treated, and recrudescent parasites 
were analyzed by immunoblot. (C) Mice infected with P. berghei ANKA were treated orally 
with 64 mg/kg AS. One day later, the normal erythrocytic stage parasites were undetectable 
by Giemsa stain and there was increased levels of phosphorylated PbeIF2α (lane 1). The 
mice were then separated into 2 groups: mice in one group were i.v. injected with Sal 
(2mg/kg) and the other group was vehicle control. 24 hours after Sal administration, normal 
erythrocytic stage parasites recurred in the control group harboring dephosphorylated 
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PbeIF2α (lane 2); recrudescence was undetectable in the Sal-treated mice and PbeIF2α was 
phosphorylated (lane 3). Two days post-Sal treatment the parasites recrudesce and their 
PbeIF2α was dephosphorylated (lane 4). (D) Sal prolongs AS-induced latency in P. berghei 
infected mice. One to five doses of AS were administered orally to the infected mice, then 
Sal was i.v. injected into mice on day 1 or on days 1–3 post-AS treatment. Giemsa stain 
(sensitivity of 0.01% parasitemia) was performed to determine recrudescent rate. (E) Sal 
prolongs DHA-induced latency in P. falciparum culture. DHA-treated P. falciparum 3D7 
cultures followed by magnetic column purification were treated with 10 μM Sal on day 2 or 
on days 2, 4, and 6 post-DHA treatment. Data are representative of 3 independent 
experiments. Related to Figure S1, S2 and Table S1.
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Figure 2. Parasites bearing phosphorylated eIF2α are less sensitive to ART
(A) Ring, trophozoite, and schizont stages of P. berghei ANKA were treated with 64 mg/kg 
AS for 15 min and levels of PbeIF2α-P and total PbeIF2α were determined by immunoblot. 
(B) Ring, trophozoite, and schizont stages of P. falciparum 3D7 were treated with 200 nM 
DHA for 15 min. Amounts of PfeIF2α-P and total PfeIF2α were determined by 
immunoblot. (C) Recrudescence of P. berghei rings, trophozoites, and schizonts following 3 
doses of 64 mg/kg AS as determined by Giemsa stain. (D) Recrudescence of P. falciparum 
rings, trophozoites, and schizonts after a 6 hour treatment with 200 nM DHA treatment, 
followed by magnetic column purification to the unaffected parasites by DHA. (E) PbeIF2α-
P levels after pre-treatment with Sal. Mice infected with asynchronized P. berghei were 
intravenously injected with 2 mg/kg Sal 24 hours before AS treatment. PbeIF2α-P levels 
were analyzed by immunoblots. (F) PfeIF2α-P levels after pre-treatment with Sal. 
Asynchronized P. falciparum were treated with 10 μM Sal for 2 hours. (G) Recrudescence 
rates of AS-treated P. berghei following increased levels of eIF2α phosphorylation by Sal 
treatment. P. berghei infected mice were intravenously injected with Sal 24 hours before the 
mice were orally administered 3 or 5 doses of 64 mg/kg AS. (H) Recrudescence rates of 
DHA-treated P. falciparum 3D7 after inflating eIF2α phosphorylation with Sal. 
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Asynchronized P. falciparum 3D7 were treated with Sal for 2 hours. The medium was then 
refreshed and the parasites were treated with 200 nM DHA for 6 hours, followed by a step of 
magnetic column purification to the unaffected parasites by DHA. Data are representative of 
3 independent experiments.
Zhang et al. Page 23
Cell Host Microbe. Author manuscript; available in PMC 2018 December 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. ART treatment and PK4 activation
(A) A box represents the PK4 protein, with the luminal domain, transmembrane domain 
(TM), and eIF2α kinase domain indicated, along with corresponding residue numbers. (B) 
Subcellular co-localization of PK4 (green) and BIP (red) as revealed by 
immunofluorescence in erythrocytic stages of P. berghei. DAPI (blue) was used as a co-stain 
to show the parasite nuclei. Scale bar, 10 μm. (C) Whole cell extracts from P. berghei blood 
stage parasites untreated or treated with AS for 15 min were immediately subjected to 
immunoprecipitation (IP) with anti-PK4 or anti-BIP antibodies followed, by immunoblot 
(IB) analysis with the designated antibody. (D) PfPK4 oligomerizes in response to DHA. 
Left panel, contents of PK4 and BIP from lysates of untreated or 200 nM DHA-treated (15 
min) P. falciparum 3D7 culture. Right panels, measurements of PK4 protein after size 
fractionation of lysates by sedimentation on a 20–40% glycerol gradient. The fractionation 
numbers are indicated and PK4 levels were measured in gradient fractions by immunoblot. 
Related to Figure S3, S4 and S5.
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Figure 4. Effect of PK4 on parasite recrudescence following ART treatment
(A) A dominant-negative form of PK4 was created by mutating the autophosphorylation site 
(T2436A), which inhibits kinase activity in vitro. GST-tagged PbPK4KD wt or T2436A 
mutant proteins were incubated with PbeIF2α and [γ-32P] ATP. Samples were then resolved 
on SDS-PAGE for autoradiography. (B) The mRNA levels of PK4 in P. berghei parasites 
harboring empty vector, episomal plasmid expressing functional PK4 with a synonymous 
codon change or a version encoding the T2436A mutant. P. berghei ring stage parasites were 
analyzed for the levels of endogenous, synonymous, and T2436A mutant PK4 mRNAs. The 
arginyl-tRNA synthetase (PbArgRS, PB000094.03.0) was used as internal control. Each 
value is the mean ± standard deviation (SD) of two independent experiments. (C) 
Expression of dominant-negative PK4 inhibits phosphorylation of P. berghei eIF2α. Levels 
of total PK4 protein, phosphorylated PbeIF2α, and total PbeIF2α in the parasites harboring 
the different episomes were revealed by immunoblotting. (D) Expression of dominant-
negative PK4 enhances protein synthesis in the parasite. Protein synthesis was analyzed by 
incorporation of [35S]Met/Cys. Each value is the mean ± SD of two independent 
experiments. (E) Expression of dominant-negative PK4 abolishes recrudescence following 
AS treatment. Mice infected with P. berghei parasites harboring the three designated 
episomes were treated with 3 doses of 64 mg/kg AS. Data are representative of 3 
independent experiments.
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Figure 5. PK4 inhibitor GSK2606414 prevents recrudescence following ART treatment
Effects of GSK2606414 on the levels of Plasmodium eIF2α phosphorylation 24 hours after 
75 mg/kg GSK2606414 treatment of mice infected with asynchronized P. berghei ANKA 
(A) and 48 hours after 2 μM GSK2606414 treatment of asynchronized P. falciparum 3D7 
parasites in culture (B). Plasmodium eIF2α phosphorylation levels were evaluated by 
immunoblot. Parasitemia ± SD of P. berghei ANKA infected mice (C) and P. falciparum 
3D7 culture (D) treated with GSK2606414 were determined by microscopy after Giemsa 
stain. Arrows indicate the two days that GSK2606414 was added. (E) Giemsa stains of P. 
falciparum 3D7 culture treated with 2 μM GSK2606414. DMSO-treated parasites complete 
the erythrocytic cycle in ~48 hours, in contrast to GSK2606414-treated parasites, which halt 
differentiation at the trophozoite stage. (F) Recrudescence of P. berghei after combination 
therapy. P. berghei infected mice were intravenously injected with 75 mg/kg Sal and 1 hr 
later were orally administered 3 or 5 doses of 64 mg/kg AS. Giemsa stain was performed to 
determine recrudescence rate. (G) Recrudescence of P. falciparum 3D7 in culture after 
combination therapy of GSK2606414 and DHA. Asynchronized P. falciparum 3D7 parasites 
were treated with 2μM GSK2606414 or DMSO for 1 hr, followed by a treatment of 200 nM 
DHA for 6 hrs. Data are representative of 3 independent experiments. Related to Figure S6.
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Figure 6. Phosphorylation of PfeIF2α in a PfK13 C580Y mutant parasite
(A) ART-resistant Dd2C580Y and ART-sensitive Dd2 parasites collected at different hours 
post the incubation of late-stage schizonts and fresh red blood cells were subjected to 
immunoblot analysis of PfeIF2α-P and total PfeIF2α. R, ring; T, trophozoite; S, schizont. 
(B) Young rings (0–3 hours post invasion of erythrocytes) of Dd2C580Y and Dd2 were 
treated with 700 nM DHA for 15 min, and PfeIF2α phosphorylation levels were evaluated 
by immunoblot. Data are representative of 3 independent experiments. (C) GSK2606414 
reduced ART resistance. Young rings (0–3 h post invasion) of the ART-resistant parasite 
Dd2C580Y and the ART-sensitive parasite Dd2 were pre-treated with 2 μM GSK2606414 for 
2 h, and then the rings (2–5 h) were treated with a pulse of 700 nM DHA for 6 h. RSA 
survival rate ± SD of the parasite was measured. DMSO-treated parasites were used as 
controls. *P<0.05; #P>0.05. Data are representative of 5 independent experiments.
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Table 1
Inhibition of P. falciparum 3D7 growth after 4 hour treatment with antimalarial drugs*.
Fluorescence (485/530 nm) Concentration Rings Trophozoites Schizonts
Amodiaquin 600 nM 5,801 5,065 93,628
Atovaquone 5 μM 5,231 5,051 6,177
Pyrimethamine 4 uM 5,579 5,477 84,981
Primaquine 1uM 102,496 6,900 67,726
DHA 200 nM 100,835 6,025 87,180
DMSO 155,341 154,326 155,253
*P. falciparum 3D7 0–3 h rings, 21–24 h trophozoites, and 32–35 h schizonts were simultaneously treated with a pulse of antimalarial drugs for 4 
hours. DMSO-treated parasites maintained their ring, trophozoite, or schizont stages during the 4 hour treatment period. Parasites were washed and 
medium was refreshed after the 4-hour drug treatment. Ninety-six hours later, parasite load was evaluated by SYBR Green I nucleic acid staining 
dye (Plouffe et al., 2008). Data are representative of 3 independent experiments. Fluorescence emissions with >10% difference relative to 
trophozoites are marked in bold.
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